Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aegis Therapeutics
Feasibility studies initiated for intranasal drug delivery in type 2 diabetes
July 6th, 2005
Edward Maggio, 858-618-1400 Aegis Therapeutics announced that the company has entered into separate agreements with two undisclosed research partners to evaluate the application of its patented Intravail technology for development of proprietary formulations for the nasal delivery of compounds useful for the treatment of type 2 diabetes and a second undisclosed metabolic disease. Financial terms are not disclosed. Aegis Therapeutics will utilize its proprietary Intravail transmucosal drug delivery technology to facilitate drug transport across the nasal mucosa. The initial feasibility studies are designed to assess the relative...
Source: Biotech Week (2005-07-06)
|
